Abstract
Estrogens and progestins synergize to increase the risk of breast cancer in post menopausal patients. Two house keeping enzymes, the estrogen-induced cathepsin D and the progestin-induced Fatty Acid Synthase (FAS) that we identified in hormone responsive breast cancer cell lines give a partial explanation for this synergy. Both cathepsin D and FAS are also induced by growth factors, their overexpression in breast cancers has a bad prognostic significance and their inhibition in nude mice decrease mammary tumor growth. The mechanism of their in vivo activity might be mediated by the internal production of nutrients allowing cancer cells to grow in restricted conditions. Their overexpression in pre invasive breast lesions is independent and occurs in both ERα positive and ERα negative breast cancers.
Keywords
- Breast Cancer
- Human Breast Cancer Cell Line
- Medroxy Progesterone Acetate
- Sporadic Breast Cancer
- Fatty Acid Synthetase
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U (1996) Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77:474–482
Bardon S, Vignon F, Chalbos D, Rochefort H (1985) RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J Clin Endocrinol Metab 60:692–697
Beral V and the MWS group (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427
Chalbos D, Vignon F, Keydar I, Rochefort H (1982) Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D). J Clin Endocrin Metab 55:276–283
Chalbos D, Chambon M, Ailhaud G, Rochefort H (1987a) Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells. J Biol Chem 262:9923–9926
Chalbos D, Haagensen D, Parish T, Rochefort H (1987b) Identification and androgen regulation of two proteins released by the T47D human breast cancer cells. Cancer Res 47:2782–2792
Clarke CL, Sutherland RL (1990) Progestin regulation of cellular proliferation. Endocr Rev 11:266–301
Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. New Engl J Med 312:146–151
Esslimani-Sahla M, Thezenas S, Simony-Lafontaine J, Kramar A, Lavaill R, Chalbos D, Rochefort H (2007) Increased expression of Fatty Acid Synthase and Progesterone receptor in early steps of human mammary carcinogenesis. Int J Cancer 120(2):224–22
Ferrandina G, Scambia G, Bardelli F, Panici B, Mancuso S, Messori A (1997) Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer 76:661–666
Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114(3):448–454
Garcia D, Derocq D, Pujol P, Rochefort H (1990) Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 5:1809–1814
Glondu M, Liaudet-Coopman E, Derocq D, Platet N, Rochefort H, Garcia M (2002) Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene 21:5127–5134
Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ 3rd, Visscher DW (2005) Benign breast disease and the risk of breast cancer. New Engl J Med 353:229–237
Ismail PM, Amato P, Soyal SM, DeMayo FJ, Conneely OM, O’Malley BW, Lydon JP (2003) Progesterone involvement in breast development and tumorigenesis – as revealed by progesterone receptor “knockout” and “knockin” mouse models. Steroids 68:779–787
Joyeux C, Chalbos D, Rochefort H (1990) Effects of progestins and menstrual cycle on fatty acid synthetase and progesterone receptor in human mammary glands. J Clin Endocrinol Metab 70:1438–1444
Kuhajda FP (2006) Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66:5977–5980
Kuhadja FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 97:3450–3454
Montcourrier P, Mangeat P, Salazar G, Morisset M, Sahuquet A, Rochefort H (1990) Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles. Cancer Res 50:6045–6054
Montcourrier P, Valembois C, Rochefort H (1993) La présence de grandes vésicules acides est correlée avec le pouvoir invasif in vitro de cellules mammaires cancéreuses. CR Acad Sci 316:421–424
Montcourrier P, Mangeat P, Valembois C, Salazar G, Sahuquet A, Duperray C, Rochefort H (1994) Characterization of very acidic phagosomes in breast cancer cells and their association with invasion. J Cell Sci 107:2381–2391
Remontet L, Esteve J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, Exbrayat C, Tretare B, Carli PM, Guizard AV, Troussard X, Bercelli P, Colonna M, Halna JM, Hedelin G, Mace-Lesec’h J, Peng J, Buemi A, Velten M, Jougla E, Arveux P, Le Bodic L, Michel E, Sauvage M, Schvartz C, Faivre J (2003) Cancer incidence and mortality in France over the period 1978–2000. Rev Epidemiol Santé Publ 51:3–30
Rochefort H (1996) The prognostic value of Cathepsin-D in Breast Cancer. A long road to the clinic. Eur J Cancer 32A:7–8
Rochefort H, Liaudet-Coopman E (1999) Cathepsin D in cancer metastasis: A protease and a ligand. APMIS 107:86–95
Rochefort H, Cavaillès V, Augereau P, Capony F, Maudelonde T, Touitou I, Garcia M (1989) Overexpression and hormonal regulation of pro-cathepsin D in mammary and endometrial cancer. J Steroid Biochem 34:77–182
Rochefort H, Garcia M, Glondu M, Laurent V, Liaudet E, Rey JM, Roger P (2000) Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 291:157–170
Rochefort H, Glondu M, Sahla ME, Platet N, Garcia M (2003) How to target estrogen receptor-negative breast cancer? Endocrine Rel Cancer 10:261–266
Roger P, Daures JP, Maudelonde T, Pignodel C, Gleizes M, Chapelle J, Marty-Double C, Baldet P, Mares P, Laffargue F, Rochefort H (2000) Dissociated overexpression of cathepsin-D and estrogen receptor alpha in preinvasive mammary tumors. Human Pathol 31:593–600
Roger P, Esslimani Sahla M, Makela S, Gustafsson J-Å, Baldet P, Rochefort H (2001) Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537–2541
Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, Köster A, Hess B, Evers M, Von Figura K, Peters C (1995) Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the mucosa and profound destruction of lymphoid cells. EMBO J 14:3599–3608
Sameni M, Moin K, Sloane BF (2000) Imaging proteolysis by living human breast cancer cells. Neoplasia 2:495–504
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou C, Lønning PE, Brown PO, Børresen-Dale AL, Botsteinet D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–842
Spyratos F, Brouillet JP, Defrenne A, Hacene K, Rouesse J, Maudelonde T, Brunet M, Andrieu C, Desplaces A, Rochefort H (1989) Cathepsin-D: an independant prognostic factor for metastasis of breast cancer. Lancet 8672:1115–1118
van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536
Vignon F, Bardon S, Chalbos D, Rochefort H (1983) Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J Clin Endocrinol Metab 56:1124–1130
Vignon F, Capony F, Chambon M, Freiss G, Garcia M, Rochefort H (1986) Autocrine growth stimulation of the MCF7 breast cancer cells by the estrogen-regulated 52k protein. Endocrinology 118:1537–1545
Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9:138–14
Wakil S (1989) Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28:4523–4530
Westley BR, Rochefort H (1980) A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20:353–362
Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–333
Writing Group for the Women’s Health Initiative Investigators (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291:1701–171
Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES (2002) Activation of Fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279:80–90
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Rochefort, H. (2008). The Synergy of Two Ovarian Hormone-induced Enzymes in Human Mammary Carcinogenesis. In: Melmed, S., Rochefort, H., Chanson, P., Christen, Y. (eds) Hormonal Control of Cell Cycle. Research and Perspectives in Endocrine Interactions. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-73855-8_10
Download citation
DOI: https://doi.org/10.1007/978-3-540-73855-8_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-73854-1
Online ISBN: 978-3-540-73855-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)